Finoriq research workspace
Generate Biomedicines, Inc. (GENB) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Generate Biomedicines, Inc. (GENB).
Company Snapshot
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
- Company
- Generate Biomedicines, Inc. (GENB)
- Ticker
- GENB
- Market Cap
- $1.7B
- Latest Price
- $13.63
- Industry
- Biotech & Pharma
Generate Biomedicines, Inc. (GENB) Recent Insider Transactions
Recent market insider transaction records indexed for Generate Biomedicines, Inc. (GENB).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Nally MichaelChief Executive Officer | P | Acquired | $240,000 | 2026-03-04 |
| Grous BethChief People Officer | P | Acquired | $4,800 | 2026-03-02 |
| Silvers JasonPresident & CFO | P | Acquired | $8,000 | 2026-03-02 |
| Silvers JasonPresident & CFO | P | Acquired | $8,000 | 2026-03-02 |
| Silvers JasonPresident & CFO | P | Acquired | $16,000 | 2026-03-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.